Transcatheter arterial embolization for advanced hepatocellular carcinoma: The controversy continues
β Scribed by Shuichi Okada
- Publisher
- John Wiley and Sons
- Year
- 1998
- Tongue
- English
- Weight
- 30 KB
- Volume
- 27
- Category
- Article
- ISSN
- 0270-9139
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
## Abstract ## BACKGROUND Systemic, highβdose interferonβΞ± treatment given three times per week subcutaneously induces tumor regression in approximately 30% of patients with inoperable hepatocellular carcinoma (HCC). The objective of the current study was to determine the efficacy and safety of tr
Background. Because transcatheter arterial embolization (TAE) has been shown to be effective in patients with unresectable hepatocellular carcinoma (HCC), the question arises whether TAE has an equivalent or superior effect on resectable HCC compared with surgery. To clarify this point, the authors
Background. Modulation of serum levels of circulating cytokines and inflammatory responses with a serine protease inhibitor was studied in 34 patients with hepatocellular carcinoma (HCC) after transcatheter arterial embolization (TAE). Methods. The 34 patients were randomly divided into two groups: